Renaissance Technologies’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-169,034
| Closed | -$8.91M | – | 3604 |
|
|
2026
Q1 | $8.91M | Sell |
169,034
-297,813
| -64% | -$12.2M | 0.01% | 1027 |
|
|
2025
Q4 | $18.9M | Sell |
466,847
-209,987
| -31% | -$4.85M | 0.03% | 631 |
|
|
2025
Q3 | $5.08M | Sell |
676,834
-245,700
| -27% | -$1.57M | 0.01% | 1485 |
|
|
2025
Q2 | $3.44M | Sell |
922,534
-511,300
| -36% | -$1.6M | ﹤0.01% | 1758 |
|
|
2025
Q1 | $3.96M | Buy |
1,433,834
+810,700
| +130% | +$3.31M | 0.01% | 1562 |
|
|
2024
Q4 | $3.45M | Buy |
623,134
+143,634
| +30% | +$973K | 0.01% | 1679 |
|
|
2024
Q3 | $4M | Buy |
479,500
+392,000
| +448% | +$3.23M | 0.01% | 1584 |
|
|
2024
Q2 | $596K | Buy |
+87,500
| New | +$530K | ﹤0.01% | 2613 |
|
|
2023
Q4 | – | Sell |
-290,100
| Closed | -$1.46M | – | 4128 |
|
|
2023
Q3 | $1.46M | Buy |
290,100
+236,900
| +445% | +$1.5M | ﹤0.01% | 2054 |
|
|
2023
Q2 | $466K | Sell |
53,200
-52,000
| -49% | -$606K | ﹤0.01% | 2909 |
|
|
2023
Q1 | $1.25M | Sell |
105,200
-9,700
| -8% | -$92.7K | ﹤0.01% | 2330 |
|
|
2022
Q4 | $1.17M | Sell |
114,900
-37,300
| -25% | -$248K | ﹤0.01% | 2437 |
|
|
2022
Q3 | $896K | Sell |
152,200
-32,216
| -17% | -$120K | ﹤0.01% | 2564 |
|
|
2022
Q2 | $457K | Buy |
184,416
+116,616
| +172% | +$233K | ﹤0.01% | 3210 |
|
|
2022
Q1 | $201K | Buy |
+67,800
| New | +$289K | ﹤0.01% | 3646 |
|
Other funds holding TERN
Renaissance Technologies's TERN Position: Q2 2026 in Review
Renaissance Technologies sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 169,034 shares — an estimated $8.91M sold.
Renaissance Technologies first reported a position in TERN in Q1 2022 and held it in 15 quarters. The position peaked at $18.9M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Renaissance Technologies reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Renaissance Technologies sold 169,034 Terns Pharmaceuticals shares in Q2 2026, an estimated $8.91M.
- Renaissance Technologies first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 15 quarters.
- Renaissance Technologies's Terns Pharmaceuticals position peaked at $18.9M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.